A detailed history of Tower Research Capital LLC (Trc) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 8,702 shares of VTYX stock, worth $19,753. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,702
Previous 12,058 27.83%
Holding current value
$19,753
Previous $27,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.85 - $3.2 $6,208 - $10,739
-3,356 Reduced 27.83%
8,702 $18,000
Q2 2024

Aug 13, 2024

SELL
$2.31 - $5.59 $6,114 - $14,796
-2,647 Reduced 18.0%
12,058 $27,000
Q1 2024

May 15, 2024

SELL
$1.9 - $10.13 $9,921 - $52,898
-5,222 Reduced 26.21%
14,705 $80,000
Q4 2023

Feb 13, 2024

BUY
$2.08 - $31.18 $38,729 - $580,571
18,620 Added 1424.64%
19,927 $49,000
Q3 2023

Nov 14, 2023

BUY
$29.8 - $40.3 $18,893 - $25,550
634 Added 94.21%
1,307 $45,000
Q2 2023

Aug 14, 2023

BUY
$28.53 - $39.55 $6,533 - $9,056
229 Added 51.58%
673 $22,000
Q1 2023

May 09, 2023

SELL
$29.51 - $46.65 $1,829 - $2,892
-62 Reduced 12.25%
444 $15,000
Q4 2022

Feb 10, 2023

SELL
$24.16 - $36.38 $35,998 - $54,206
-1,490 Reduced 74.65%
506 $16,000
Q3 2022

Nov 10, 2022

BUY
$12.64 - $38.7 $2,313 - $7,082
183 Added 10.09%
1,996 $70,000
Q2 2022

Aug 15, 2022

BUY
$11.95 - $18.75 $10,181 - $15,975
852 Added 88.66%
1,813 $22,000
Q1 2022

May 12, 2022

BUY
$10.0 - $19.98 $4,140 - $8,271
414 Added 75.69%
961 $13,000
Q4 2021

Feb 14, 2022

BUY
$14.2 - $23.07 $7,767 - $12,619
547 New
547 $11,000

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $128M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.